Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ARK Genomic Revolution ETF (NY:ARKG)

25.93 +0.33 (+1.29%)
Official Closing Price Updated: 8:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARK Genomic Revolution ETF

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
ETF Returns: Mid-Cap Winners And Losers
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on... 
Via Benzinga
Cathie Wood's Ark Outshines S&P 500, Nasdaq In H1: Here Are The Major Trades It Made
 
Via Benzinga
This Big Cathie Wood Stock Is Outperforming Even Tesla
DraftKings is the strongest performer among Ark Invest's major holdings. 
Via Investor's Business Daily
Evogene - A Company With Valuable Assets Trading At Zero Enterprise Value
From a sum-of-parts perspective, Evogene is likely worth many multiples of its market valuation today, even without ascribing any value to Evogene’s technology. 
Via Talk Markets
Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy
Success could be in the DNA of the Ark Invest founder. 
Via The Motley Fool
Your Guide to All 6 Cathie Wood ETFs
Here's what investors need to know about all the Ark Invest ETFs. 
Via The Motley Fool
A Bull Market Is Coming: These 2 Cathie Wood Stocks Could Skyrocket
Wood sees the long-term potential in these two innovators. 
Via The Motley Fool
Cathie Wood Trimmed This Big Tech Stock Holding But Bulked Up On SaaS Provider PagerDuty And Ginkgo Bioworks
 
Via Benzinga
Cathie Wood Sells More Nvidia Shares After Rally: Here's How Many Shares Ark Funds Owns Of AI Giant
One of the most notable exchange-traded fund families may have sold shares of Nvidia Corporation (NASDAQ: NVDA) early. The Ark Funds ETFs have continued selling Nvidia shares since the company reported... 
Via Benzinga
Did Cathie Wood's Innovation ARKK ETF Whiff On AI? How It Compares To FAANG, Nvidia In 2023
One of the most recognizable investing names of the last decade is Ark Funds CEO Cathie Wood. With an eye on high-growth stocks and innovation, the Ark Funds outperformed the market for years during... 
Via Benzinga
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
 
Via Benzinga
Cathie Wood Trims Stake In This Chinese E-Commerce Giant – Loads Up On Butterfly Network Stock
 
Via Benzinga
Move Over, ChatGPT: 5 Stock Ideas For Leveraging The Power Of AI In Health Care, Cybersecurity
Generative artificial intelligence has taken the world by storm in 2023. 
Via Benzinga
10 Best Stocks to Buy in March 2023
These diversified growth stocks could add rocket fuel to your long-term investment portfolio. 
Via The Motley Fool
Cathie Wood Makes Biggest Coinbase Purchase Of Year After Earnings Beat
Cathie Wood and her ARK Invest firm bought $13 million in COIN stock as they bulk up holdings following Coinbase earnings. 
Via Investor's Business Daily
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
These stocks are risky. But they just might deliver huge gains if analysts are right. 
Via The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy? 
Via Talk Markets
Cathie Wood Trims Robinhood Stake As Stock Gains 28% In January — Also Offloads Shares In This Biotech Company
Cathie Wood-led ARK Investment Management sold 85,337 shares of financial services company Robinhood Markets Inc (NASDAQ: HOOD) at 
Via Benzinga
Why Teladoc Stock Popped 5% Today
Cathie Wood keeps buying shares of the telemedicine company. Should you? 
Via The Motley Fool
Healthcare Sector Is Lagging As We Enter 2022 Earnings Season
The healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength. 
Via Talk Markets
Don't Call It A Comeback: Cathie Wood Is Beating The S&P 500 In Early 2023
The competition could be paying the price in 2023 if Ark Invest can keep up with its early performance at the start of the year. 
Via Benzinga
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing. 
Via Talk Markets
Cathie Wood Makes This Molecular Diagnostics Company Top Holding Of Ark Invest's Flagship Fund, Catapulting Past Zoom, Tesla
Shares of Exact Sciences, Inc. (NASDAQ: EXAS) have been on a tear, having gained over 27% in two sessions this week. 
Via Benzinga
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams. 
Via Benzinga
War, Inflation, Fed Hawkishness, Elon Musk's Twitter Buy: How These Factors Weighed On Cathie Wood's Top Holdings In 2022
In 2022, financial markets witnessed one of the worst routs in history, dragged by the war in Ukraine, rising inflation and subsequent hawkish policies deployed by central banks. 
Via Benzinga
Precious Metals Outperformed Stocks And Bonds In 2022
The power of silver's rebound has surprised many, even its most ardent supporters. 
Via Talk Markets
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
These two biotechs are flying high right now. 
Via The Motley Fool
'Study The Mindset Of Stonk Hodlers': This Fund Manager Rips Cathie Wood's Investment Strategy
ETF fund manager Cathie Wood is known for investing in growth stocks and what she has labeled as “innovation.” A take by the fund manager drew criticism from a hedge fund manager. 
Via Benzinga
Cathie Wood Adds $7M Of This Clinical-Stage Biotech, Trims Stake In CVS-Target Signify Health
Cathie Wood-led ARK Investment Management bought over 330,000 shares of clinical-stage biotechnology company Verve Therapeutics Inc (NASDAQ: VERV) at an estimated valuation of over $6.9 million, based... 
Via Benzinga
Getting Ready For The Coming Stock Market Elevator Drop
In this video Kirk Spano updates trends in Global ETFs and discusses why he thinks stocks are headed down in a big way. 
Via Talk Markets
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.